Novo Nordisk has received US regulatory approval for Wegovy® HD (semaglutide 7.2 mg), representing a significant advancement in pharmacological obesity management. This higher-dose formulation of the GLP-1 receptor agonist semaglutide is designed to address unmet needs in patients who do not achieve adequate weight loss with existing therapies. The approval is supported by robust data from the phase 3 STEP UP clinical trial program, which evaluated the efficacy and safety of once-weekly semaglutide 7.2 mg in adults with obesity.
In the pivotal 72-week trial involving individuals without type 2 diabetes, treatment with Wegovy® HD resulted in a mean body weight reduction of 20.7%, significantly exceeding the weight loss observed with the currently approved 2.4 mg dose (approximately 17–17.5%) and placebo (approximately 2–4%). Notably, around one-third of participants receiving the 7.2 mg dose achieved at least 25% weight loss, underscoring the potential of higher-dose semaglutide to deliver clinically meaningful and substantial outcomes.
The enhanced efficacy of Wegovy® HD is particularly relevant in the context of chronic weight management, where greater and sustained weight reduction is associated with improvements in cardiometabolic risk factors and obesity-related complications. The higher dose provides an additional therapeutic option for patients who have plateaued on lower doses, offering clinicians greater flexibility in individualizing treatment strategies.
Safety findings for the 7.2 mg dose were generally consistent with the established profile of GLP-1 receptor agonists, with gastrointestinal adverse events such as nausea and vomiting being the most commonly reported. While higher doses may increase the frequency of such events, the overall benefit–risk profile remains favorable in appropriately selected patients. The US approval of Wegovy® HD reinforces the expanding role of incretin-based therapies in obesity care and reflects ongoing innovation aimed at achieving greater efficacy. As competition intensifies in the anti-obesity therapeutic landscape, this higher-dose semaglutide formulation positions Novo Nordisk to address increasing demand for more effective weight management solutions while advancing clinical outcomes in obesity treatment.
